Top in allergy/asthma: Modified anaphylaxis criteria; oral immunotherapy for children
Click Here to Manage Email Alerts
A recent study found that health care professionals were increasingly able to identify infants and young children with anaphylaxis by following modified criteria.
The current criteria for identifying anaphylaxis, published by the National Institute of Allergy and Infectious Diseases (NIAID) and the Food Allergy and Anaphylaxis Network (FAAN), is not validated for infants and children aged 2 years or younger. The researchers identified anaphylaxis symptoms that were specific to infants and toddlers, developed clinical criteria, and compared those findings to the existing guidelines.
“Compared to the NIAID/FAAN guidelines, our modified criteria account for age-specific differences, including the addition of surrogate signs to replace subjective symptoms as well as the incorporation of signs of compensated shock and cardiovascular compromise, such as tachycardia, cyanosis and mental status change, to supplement signs and symptoms of decompensated shock currently incorporated within the NIAID/FAAN criteria, such as hypotension,” Michael Pistiner, MD, MMSc, director of food allergy advocacy, education and prevention, Mass General for Children, told Healio.
It was the top story in allergy/asthma last week.
In another top story, a study of 97 infants and toddlers with peanut allergy showed that 67% of caregivers pursued peanut oral immunotherapy (OIT) for their children — most of them hoping to increase their children’s chances of achieving allergy remission. Those who did not said they felt peanut OIT would not improve their child’s quality of life.
Read these and more top stories in allergy/asthma below:
Modified guidelines identify anaphylaxis in more infants, young children
Modified criteria that incorporated symptoms specific to infants and young children increased identification of anaphylaxis in these age groups, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Caregivers of infants, toddlers with peanut allergy show interest in oral immunotherapy
Families of children with peanut allergies that pursued oral immunotherapy cited remission and the potential for disease modification as their reason, according to a study published in The Journal of Allergy and Immunology: In Practice. Read more.
KalVista Pharmaceuticals submits FDA application for sebetralstat
KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema, according to a company press release. Read more.
Physician recommends creative thinking to achieve career ambitions, manage your practice
Over her 20 years as an allergist, Vivian Hernandez-Trujillo, MD, created a combined allergy/immunology division and a fellowship program at her workplace and, when she craved more career control, she also opened her own practice. Hernandez-Trujillo advises young allergists to be creative when figuring out how to achieve work-life balance. Read more.
Patients pursuing OIT for peanut allergies may face racial, socioeconomic disparities
Significant disparities exist between patients with peanut allergies who are currently receiving oral immunotherapy and those who are not, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.